Dean Cheramie

It's happening! My daughter Annelise (Li) will be treated in Japan in August for debilitating POTS, dizziness, neuropathy, headaches, brain fog, GI disruption, and crushing exhaustion, with a long history of hEDS and MCAS issues. DFPA filtration for removal of amyloidogenic clotting, and restorative treatment for the vascular system, and heart, brain, and organ tissue. Bravest and strongest person I know (other than her Mom). Bless the McCairn-Edogawa team. 🙏

Attention all medical doctors, surgeons, radiologist, anesthesiologist your patients have micro clots caused by the spike proteins and Covid or the vaccination. The studies are on the news every day. Some Patient that are alive, have elastic clots, and some people’s blood is turning into a hydrogel. This is real world 100% scientific data. If you are not listening and letting your ego getting in the way of treating your patience you belong in a different profession. Help your patience survive this monstrosity and get on board with getting the shots off the market and learning how to treat the clotting. Autoimmune, cardiac, cancer, neuropathy is all far too common and all of the Injured. Put your ego aside step up and be a part of the solution, not part of the problem. We are the data.

To my X followers, including the fake and catfish accounts: For some time I have been the target of sustained personal harassment on this platform, much of it from anonymous and impersonating accounts. I have stayed quiet and kept working. I am addressing it now, once, and then returning to the science. I am not the only one. A number of researchers working on the biological basis of this illness, including collaborators of mine, have faced the same pattern of harassment. Much of it appears coordinated and comes from a small number of accounts whose interest is clearly not the science: their aim is not scientific debate; it is to intimidate people for doing research they do not like. Targeting scientists for studying a disease is not scepticism; it is intimidation. On the facts: the claim that our work "has not been replicated" is untrue. Independent groups have confirmed or applied these findings: - the same aggregates were confirmed in pulmonary embolism (Baker et al., Communications Medicine, 2023); - amyloid-fibrinogen aggregates predicted disseminated intravascular coagulation and mortality in sepsis (Schofield/Toh et al., Blood Advances, 2024); -increased fibrinaloid microclots were found in Long COVID by an independent UK group (Dalton et al., Sheffield Hallam, preprint, 2024); - and the methods have been taken up in paediatric Long COVID (Steifman, Yonker et al., Pediatric Research, 2026). This is now a field with dozens of independent papers. One thing to make very clear: I have no involvement in any apheresis or plasmapheresis treatment for these conditions. Why? It is simply not my field of expertise. I cannot control how others use published methods, and it is wrong to attribute their choices to me. On Biocode, our start-up company: public universities have a clear responsibility to translate research into public benefit, and commercialising discoveries through spin-out companies is a core part of that mandate. That is precisely what Biocode was created to do. It is an early-stage university spin-out, it is not profitable, and repeated insinuations that I am personally enriching myself are false. I welcome robust scientific criticism; that is how science works, and II have actively reached out to colleagues who see the field differently. Harassment, account stalking, impersonation and personal attacks are not criticism. I am documenting it, I am taking advice on my options, and I will not be engaging with it further. Just because biological researchers are targeted in this way does not mean we will stop. If anything, it strengthens our resolve to understand diseases and to serve the millions of patients who are waiting for answers.

Systemic capillary leak syndrome (SCLS) is absolutely a recognized adverse event from the COVID shots. This isn't fringe speculation — it's documented in the medical literature and acknowledged by regulatory bodies, even if they've downplayed the scope. What the Evidence Shows The mechanism isn't mysterious. The spike protein — whether from the virus or from the shots — is vasculotoxic. It binds to ACE2 receptors which are abundant in endothelial cells lining your blood vessels. When those cells get damaged, the tight junctions between them loosen, and plasma starts leaking into surrounding tissues. That's SCLS in a nutshell. Case reports started appearing in the literature within months of the rollout. Patients presenting with the classic triad: hypotension, hemoconcentration, and hypoalbuminemia — blood pressure crashing, blood thickening because the fluid component is leaking out, and albumin levels dropping for the same reason. Some had no prior history. Others had pre-existing monoclonal gammopathy of undetermined significance (MGUS), which is a known risk factor for SCLS, and the shot appears to have triggered a full-blown episode. What VAERS Shows VAERS, for all its limitations, captures the signal. Searching for capillary leak reports post-vaccination returns a non-trivial number of cases — many in people with no prior SCLS history. The CDC's own passive surveillance picked this up. But passive surveillance systems miss the vast majority of adverse events, so what we're seeing is almost certainly the tip of an iceberg. The Spike-Endothelial Interface The core problem is that the shots deliver instructions for your own cells to manufacture spike protein, and there's no way to control where it goes or how much is produced. Spike protein has direct cytotoxic effects on endothelial cells. This isn't theoretical — perfusion studies and in vitro work have demonstrated endothelial barrier disruption from spike exposure. When capillary beds become permeable, in severe cases you get compartment syndrome, limb ischemia, multi-organ failure. Several deaths have been attributed to post-vaccination SCLS. Bottom Line Yes, COVID shots can cause systemic capillary leak syndrome. The question isn't whether — it's how often, and the answer is almost certainly more often than the official numbers suggest. The same institutions that spent two years calling myocarditis "mild and self-limiting" before quietly admitting it's a real problem are doing the same thing here. The pattern is identical: acknowledge a few cases, call them "rare," and move on without investigating the true scope.